

Agathe Leon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2968752/publications.pdf>

Version: 2024-02-01

79
papers

3,723
citations

147566

31
h-index

133063

59
g-index

83
all docs

83
docs citations

83
times ranked

4389
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent HIV controllers are more prone to spontaneously clear HCV: a retrospective cohort study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25607.	1.2	2
2	Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients. <i>Frontiers in Genetics</i> , 2020, 11, 497.	1.1	13
3	Indicator condition-guided HIV testing with an electronic prompt in primary healthcare: a before and after evaluation of an intervention. <i>Sexually Transmitted Infections</i> , 2019, 95, 238-243.	0.8	11
4	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet</i> , The, 2019, 393, 2428-2438.	6.3	627
5	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 667-671.	1.5	14
6	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. <i>Journal of Infectious Diseases</i> , 2019, 219, 867-876.	1.9	23
7	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. <i>BMC Medicine</i> , 2018, 16, 30.	2.3	19
8	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. <i>Clinical Microbiology and Infection</i> , 2018, 24, 540-545.	2.8	13
9	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	58
10	Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients. <i>International Journal of Medical Sciences</i> , 2018, 15, 95-100.	1.1	2
11	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. <i>Frontiers in Immunology</i> , 2018, 9, 1399.	2.2	3
12	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2857-2861.	1.3	12
13	Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. <i>Frontiers in Immunology</i> , 2017, 8, 836.	2.2	10
14	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. <i>Aids</i> , 2016, 30, 553-562.	1.0	6
15	Rate and predictors of progression in elite and viremic HIV-1 controllers. <i>Aids</i> , 2016, 30, 1209-1220.	1.0	69
16	An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. <i>Trials</i> , 2016, 17, 163.	0.7	36
17	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Case-Control Study. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1016-1021.	0.5	4
18	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1982-1986.	1.3	9

#	ARTICLE	IF	CITATIONS
19	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1987-1993.	1.3	16
20	Analysis of Non-AIDS-Defining Events in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2016, 62, 1304-1309.	2.9	34
21	Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. <i>Journal of Leukocyte Biology</i> , 2016, 99, 349-359.	1.5	20
22	Shared Care Unit: a new model of coordinating HIV care between Primary Settings and Hospital. <i>International Journal of Integrated Care</i> , 2016, 16, 200.	0.1	1
23	Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. <i>Aids</i> , 2015, 29, 1309-1318.	1.0	10
24	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. <i>Journal of Virology</i> , 2015, 89, 9189-9199.	1.5	33
25	Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. <i>Aids</i> , 2015, 29, 675-681.	1.0	31
26	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	1.3	56
27	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. <i>Journal of Infectious Diseases</i> , 2015, 211, 936-946.	1.9	18
28	Differential MicroRNA Expression Profile between Stimulated PBMCs from HIV-1 Infected Elite Controllers and Viremic Progressors. <i>PLoS ONE</i> , 2014, 9, e106360.	1.1	52
29	Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. <i>Journal of the International AIDS Society</i> , 2014, 17, 19246.	1.2	17
30	Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 425-433.	0.5	8
31	A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. <i>Science Translational Medicine</i> , 2013, 5, 166ra2.	5.8	193
32	Dendritic cell based vaccines for HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2445-2452.	1.4	57
33	Comparison of two HIV testing strategies in primary care centres: indicator condition-guided testing vs. testing of those with non-indicator conditions. <i>HIV Medicine</i> , 2013, 14, 33-37.	1.0	21
34	Rate and Predictors of Non-AIDS Events in a Cohort of HIV-Infected Patients with a CD4 T Cell Count Above 500 Cells/mm ³ . <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1161-1167.	0.5	39
35	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq1 1 0.784314 rBT /Overlo	1.1	145
36	Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine. <i>Antiviral Therapy</i> , 2012, 17, 337-346.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Reasons for Not Participating in a Phase 1 Preventive HIV Vaccine Study in a Resource-Rich Country. <i>AIDS Patient Care and STDs</i> , 2012, 26, 379-382.	1.1	4
38	Therapeutic vaccines against HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 569-581.	1.4	55
39	Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. <i>Vaccine</i> , 2012, 30, 3703-3709.	1.7	22
40	Loading dendritic cells from HIV-1 infected patients with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. <i>Retrovirology</i> , 2012, 9, .	0.9	0
41	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. <i>Vaccine</i> , 2011, 29, 5711-5724.	1.7	9
42	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). <i>Vaccine</i> , 2011, 29, 8309-8316.	1.7	70
43	Lymphoid Tissue Collagen Deposition in HIV-Infected Patients Correlates With the Imbalance Between Matrix Metalloproteinases and Their Inhibitors. <i>Journal of Infectious Diseases</i> , 2011, 203, 810-813.	1.9	19
44	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 473-478.	1.9	105
45	A New Multidisciplinary Home Care Telemedicine System to Monitor Stable Chronic Human Immunodeficiency Virus-Infected Patients: A Randomized Study. <i>PLoS ONE</i> , 2011, 6, e14515.	1.1	71
46	Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. <i>Aids</i> , 2010, 24, F1-F9.	1.0	60
47	Effect of TNF- α genetic variants and CCR5 Δ 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. <i>BMC Medical Genetics</i> , 2010, 11, 63.	2.1	24
48	Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. <i>Aids</i> , 2010, 24, 2029-2039.	1.0	37
49	Increased α -Defensins 1-3 Production by Dendritic Cells in HIV-Infected Individuals Is Associated with Slower Disease Progression. <i>PLoS ONE</i> , 2010, 5, e9436.	1.1	40
50	Assessment of migration of HIV-1-loaded dendritic cells labeled with ¹¹¹ In-oxine used as a therapeutic vaccine in HIV-1-infected patients. <i>Immunotherapy</i> , 2009, 1, 347-354.	1.0	8
51	P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02). <i>Retrovirology</i> , 2009, 6, .	0.9	0
52	Temporal Data Mining of HIV Registries: Results from a 25 Years Follow-Up. <i>Lecture Notes in Computer Science</i> , 2009, , 56-60.	1.0	1
53	Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts [*] . <i>HIV Medicine</i> , 2008, 9, 221-226.	1.0	55
54	Short Communication: Natural Killer Cells and Expression of KIR Receptors in Chronic HIV Type 1-Infected Patients after Different Strategies of Structured Therapy Interruption. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1485-1495.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Zidovudine/Lamivudine/Abacavir Plus Tenofovir in HIV-Infected Naive Patients: A 96-Week Prospective One-Arm Pilot Study. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 931-934.	0.5	8
56	Prevalence and Clinical Relevance of Occult Hepatitis B in the Fibrosis Progression and Antiviral Response to INF Therapy in HIV/HCV-Coinfected Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 547-553.	0.5	15
57	Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 184-188.	1.3	8
58	Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 174-178.	0.9	29
59	Noninvasive Diagnosis of Hepatic Fibrosis in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 304-311.	0.9	36
60	Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 824-830.	1.3	13
61	Clinicoimmunological Progression and Response to Treatment of Long-Term Nonprogressor HIV/Hepatitis C Virus-Coinfected Patients. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 863-867.	0.5	6
62	P1912 Efficacy and safety of tenofovir, abacavir and efavirenz in treatment-naïve patients:48-week results (The ABATE Trial). <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S548-S549.	1.1	0
63	Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count < 300 cells/L who were assigned to 7.5 MIU interleukin-2. <i>HIV Medicine</i> , 2007, 8, 112-123.	1.0	7
64	Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. <i>HIV Medicine</i> , 2007, 8, 251-258.	1.0	110
65	The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. <i>Antiviral Therapy</i> , 2007, 12, 407-416.	0.6	60
66	Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations. <i>Aids</i> , 2006, 20, 1891-1892.	1.0	5
67	Intrathoracic fat in HIV-infected patients. <i>HIV Medicine</i> , 2006, 7, 213-217.	1.0	4
68	Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. <i>Aids</i> , 2006, 20, 59-66.	1.0	153
69	Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. <i>Aids</i> , 2005, 19, 829-831.	1.0	3
70	High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. <i>Aids</i> , 2005, 19, 1695-1697.	1.0	18
71	Early virological failure in treatment-naïve HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. <i>Aids</i> , 2005, 19, 213-215.	1.0	48
72	Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. <i>Antiviral Therapy</i> , 2005, 10, 423-9.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Incidence and Risk Factors for Mitochondrial Toxicity in Treated HIV/HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2005, 10, 423-429.	0.6	36
74	Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz. <i>Antiviral Therapy</i> , 2005, 10, 171-177.	0.6	47
75	Risk of Metabolic Abnormalities in Patients Infected with HIV Receiving Antiretroviral Therapy that Contains Lopinavir/Ritonavir. <i>Clinical Infectious Diseases</i> , 2004, 38, 1017-1023.	2.9	75
76	Gynecomastia among HIV-Infected Patients Is Associated with Hypogonadism: A Case-Control Study. <i>Clinical Infectious Diseases</i> , 2004, 39, 1514-1519.	2.9	33
77	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. <i>Aids</i> , 2004, 18, 27-36.	1.0	343
78	Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2004, 9, 905-909.	0.6	32
79	Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 2003, 349, 1036-1046.	13.9	303